Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy~2. Subjects/Parents have been informed properly regarding the study and signed the informed consent form~3. Subject/parents/legal guardians will commit themselves to comply with the instructions of the investigator and the schedule of the trial.~Exclusion Criteria For adults-adolescent-children:~1. Subject concomitantly enrolled or scheduled to be enrolled in another trial~2. Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C)~3. Known history of allergy to any component of the vaccines~4. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~5. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, corticosteroid therapy and other immunosuppresant).~6. Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives~7. Pregnancy \& lactation (Adults)~8. Individuals who have previously received any vaccines against typhoid fever.~9. Subjects already immunized with any vaccine within 1 month prior and expect to receive other vaccines within 1 month following immunization.~10. Individuals who have a previously ascertained typhoid fever within 3 months prior to immunization.~11. History of substance abuse (Adults).~12. Subject planning to move from the study area before the end of study period.~Exclusion Criteria for infants:~1. Subject concomitantly enrolled or scheduled to be enrolled in another trial~2. Mother less than 18 years of age at the age of enrollment of the infant~3. Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C)~4. Known history of allergy to any component of the vaccines~5. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~6. Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, corticosteroid therapy and other immunosuppresant).~7. Any abnormality or chronic disease which according to the investigator might be compromised by the vaccination and/or interfere with the assessment of the trial objectives.~8. Individuals who have previously received any vaccines against typhoid fever.~9. Subjects already immunized with any vaccine within 1 month prior and expect to receive other vaccines within 1 month following immunization, except MR vaccine.~10. Individuals who have a previously ascertained typhoid fever within 3 months prior to immunization.~11. Subject planning to move from the study area before the end of study period.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- VI-DT vaccine (adults,adolescent) (Type: EXPERIMENTAL): 1 dose of 0.5 ml Vi-DT vaccine
- Vi polysaccharide (adults,adolescent) (Type: ACTIVE_COMPARATOR): 1 dose of 0.5 ml Vi polysaccharide vaccine
- VI-DT vaccine (children) (Type: EXPERIMENTAL): 1 dose of 0.5 ml Vi-DT vaccine
- Vi polysaccharide vaccine (children) (Type: ACTIVE_COMPARATOR): 1 dose of 0.5 ml Vi polysaccharide vaccine
- VI-DT vaccine (infants) (Type: EXPERIMENTAL): 1 dose of 0.5 ml Vi-DT vaccine
- IPV Vaccine (infants) (Type: ACTIVE_COMPARATOR): 1 dose of 0.5 ml IPV vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).